Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives

Standard

Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives. / Guryanov, Ivan ; Tennikova, Tatiana ; Urtti , Arto .

In: Pharmaceutics, Vol. 13, No. 9, 1337, 09.2021.

Research output: Contribution to journal › Review article › peer-review

BibTeX

@article{1713733961924a15b4692f57ec84480d,

title = "Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives",

abstract = "Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs",

keywords = "VEGF, VEGFA, VEGFR, peptide, affinity, binding, angiogenesis, Binding, Angiogenesis, Affinity, Peptide",

author = "Ivan Guryanov and Tatiana Tennikova and Arto Urtti",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = sep,

doi = "10.3390/pharmaceutics13091337",

language = "English",

volume = "13",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI AG",

number = "9",

}

RIS

TY - JOUR

T1 - Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives

AU - Guryanov, Ivan

AU - Tennikova, Tatiana

AU - Urtti , Arto

PY - 2021/9

Y1 - 2021/9

N2 - Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs

AB - Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs

KW - VEGF

KW - VEGFA

KW - VEGFR

KW - peptide

KW - affinity

KW - binding

KW - angiogenesis

KW - Binding

KW - Angiogenesis

KW - Affinity

KW - Peptide

UR - https://www.mdpi.com/1999-4923/13/9/1337

UR - http://www.scopus.com/inward/record.url?scp=85114107167&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics13091337

DO - 10.3390/pharmaceutics13091337

M3 - Review article

VL - 13

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 9

M1 - 1337

ER -

ID: 84964670